Journal
LEUKEMIA & LYMPHOMA
Volume 60, Issue 7, Pages 1610-1625Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2018.1564828
Keywords
Aggressive B-cell non-Hodgkin lymphoma; autologous stem cell transplantation; relapsed; refractory; standard-of-care; structured review
Categories
Funding
- Servier (Suresnes, France)
Ask authors/readers for more resources
Aggressive B-cell non-Hodgkin lymphoma (aNHL) accounts for similar to 50% of all NHL cases. The only potentially curative, broadly available treatment for patients with relapse, failing frontline treatment, is high-dose therapy followed by autologous stem cell transplantation (ASCT); patients ineligible for/who have failed ASCT have limited standard-of-care options. We conducted a structured review of treatments for relapsed/refractory patients with aNHL based on literature published between 2006 and 2017. Of the 22 publications identified for inclusion, most described phase II, single-arm trials (N=25-217), and only three were randomized studies (phase II [N=96], phase II/III [N=111] and phase III [N=338]). The majority of treatments evaluated resulted in only modest efficacy (median progression-free survival, 2.1-20.0months) and ultimately poor health outcomes (median overall survival, 25weeks-15.5months). In conclusion, there is an unmet need for novel, effective, and tolerable treatments for patients with relapsed/refractory aNHL who are ineligible for/have failed ASCT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available